Do analysts prefer ALZN or BYSI?

Alzamend Neuro currently has a consensus target price of $28.00, suggesting a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALZN or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.74% -200.07% BeyondSpring N/A N/A -28.88%

Do analysts prefer ALZN or LTRN?

Alzamend Neuro presently has a consensus price target of $28.00, suggesting a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ALZN or LTRN?

Lantern Pharma is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$8.77M -$2.90 N/A Lantern Pharma N/A N/A -$17.12M -$1.62 N/A

Is ALZN or LTRN more profitable?

Alzamend Neuro's return on equity of -277.74% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.74% -200.07% Lantern Pharma N/A -368.02% -148.62%

Is EVAX or ALZN more profitable?

Evaxion A/S's return on equity of -61.43% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% Alzamend Neuro N/A -277.74% -200.07%

Does the media favor EVAX or ALZN?

In the previous week, Alzamend Neuro had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 8 mentions for Alzamend Neuro and 7 mentions for Evaxion A/S. Alzamend Neuro's average media sentiment score of 0.65 beat Evaxion A/S's score of -0.21 indicating that Alzamend Neuro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALZN or GNTA?

Alzamend Neuro currently has a consensus price target of $28.00, indicating a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ALZN or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$8.77M -$2.90 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is ALZN or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -277.74% -200.07% Genenta Science N/A N/A N/A

Does the media refer more to ALZN or GNTA?

In the previous week, Alzamend Neuro had 6 more articles in the media than Genenta Science. MarketBeat recorded 8 mentions for Alzamend Neuro and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat Alzamend Neuro's score of 0.65 indicating that Genenta Science is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ENLV or ALZN?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Alzamend Neuro N/A N/A -$8.77M -$2.90 N/A

Is ENLV or ALZN more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Alzamend Neuro N/A -277.74% -200.07%

Does the media refer more to ENLV or ALZN?

In the previous week, Alzamend Neuro had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 8 mentions for Alzamend Neuro and 4 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.88 beat Alzamend Neuro's score of 0.65 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alzamend Neuro (ALZN) Competitors

$1.60 -0.06 (-3.61%)

As of 03:59 PM Eastern

Compare

ALZN vs. BYSI, LTRN, EVAX, GNTA, and ENLV

Should you buy Alzamend Neuro stock or one of its competitors? Alzamend Neuro's main competitors and comparable companies include BeyondSpring (BYSI), Lantern Pharma (LTRN), Evaxion A/S (EVAX), Genenta Science (GNTA), and Enlivex Therapeutics (ENLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alzamend Neuro compare to BeyondSpring?

Alzamend Neuro (NASDAQ:ALZN) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

In the previous week, Alzamend Neuro had 7 more articles in the media than BeyondSpring. MarketBeat recorded 8 mentions for Alzamend Neuro and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.89 beat Alzamend Neuro's score of 0.65 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Alzamend Neuro	Positive
BeyondSpring	Very Positive

BeyondSpring has higher revenue and earnings than Alzamend Neuro. BeyondSpring is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A
BeyondSpring	$1.75M	14.58	-$1.01M	-$0.12	N/A

Alzamend Neuro currently has a consensus target price of $28.00, suggesting a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.74%	-200.07%
BeyondSpring	N/A	N/A	-28.88%

Summary

BeyondSpring beats Alzamend Neuro on 8 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Lantern Pharma?

Alzamend Neuro (NASDAQ:ALZN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Alzamend Neuro has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

Lantern Pharma is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

Alzamend Neuro's return on equity of -277.74% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.74%	-200.07%
Lantern Pharma	N/A	-368.02%	-148.62%

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 8.5% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Alzamend Neuro had 7 more articles in the media than Lantern Pharma. MarketBeat recorded 8 mentions for Alzamend Neuro and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.89 beat Alzamend Neuro's score of 0.65 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Alzamend Neuro	Positive
Lantern Pharma	Very Positive

Alzamend Neuro presently has a consensus price target of $28.00, suggesting a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Alzamend Neuro beats Lantern Pharma on 7 of the 12 factors compared between the two stocks.

How does Alzamend Neuro compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Evaxion A/S's return on equity of -61.43% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Alzamend Neuro	N/A	-277.74%	-200.07%

Evaxion A/S currently has a consensus target price of $11.00, suggesting a potential upside of 266.67%. Alzamend Neuro has a consensus target price of $28.00, suggesting a potential upside of 1,650.00%. Given Alzamend Neuro's higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Evaxion A/S has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

In the previous week, Alzamend Neuro had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 8 mentions for Alzamend Neuro and 7 mentions for Evaxion A/S. Alzamend Neuro's average media sentiment score of 0.65 beat Evaxion A/S's score of -0.21 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evaxion A/S has higher revenue and earnings than Alzamend Neuro. Evaxion A/S is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.32	-$7.71M	-$1.21	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A

Summary

Evaxion A/S beats Alzamend Neuro on 9 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Genenta Science?

Alzamend Neuro (NASDAQ:ALZN) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alzamend Neuro currently has a consensus price target of $28.00, indicating a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genenta Science's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.74%	-200.07%
Genenta Science	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

In the previous week, Alzamend Neuro had 6 more articles in the media than Genenta Science. MarketBeat recorded 8 mentions for Alzamend Neuro and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.94 beat Alzamend Neuro's score of 0.65 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genenta Science	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alzamend Neuro has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Summary

Genenta Science beats Alzamend Neuro on 6 of the 11 factors compared between the two stocks.

How does Alzamend Neuro compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Enlivex Therapeutics' return on equity of 248.08% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Alzamend Neuro	N/A	-277.74%	-200.07%

Alzamend Neuro is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A

In the previous week, Alzamend Neuro had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 8 mentions for Alzamend Neuro and 4 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.88 beat Alzamend Neuro's score of 0.65 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics presently has a consensus target price of $247.50, indicating a potential upside of 19,235.94%. Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 1,650.00%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

Summary

Enlivex Therapeutics beats Alzamend Neuro on 9 of the 12 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.01M	$3.92B	$7.12B	$12.85B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	N/A	11.69	272.89	25.51
Price / Sales	N/A	1,396.48	686.41	123.12
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	8.42	16.81	11.06	6.34
Net Income	-$8.77M	-$22.71M	$3.47B	$349.45M
7 Day Performance	3.23%	2.89%	1.28%	-0.10%
1 Month Performance	22.14%	13.06%	8.29%	4.36%
1 Year Performance	-34.43%	55.07%	24.29%	14.91%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	3.2831 of 5 stars	$1.60 -3.6%	$28.00 +1,650.0%	-32.0%	$8.01M	N/A	N/A	4
BYSI BeyondSpring	0.7913 of 5 stars	$0.69 -3.8%	N/A	-61.3%	$28.99M	$1.75M	N/A	80	Positive News Gap Down
LTRN Lantern Pharma	0.7153 of 5 stars	$2.15 -1.4%	N/A	-49.3%	$27.61M	N/A	N/A	20	Positive News
EVAX Evaxion A/S	1.8736 of 5 stars	$3.33 -0.5%	$11.00 +230.0%	+9.5%	$27.48M	$7.53M	N/A	60
GNTA Genenta Science	0.8619 of 5 stars	$1.12 -2.5%	N/A	-74.5%	$27.01M	N/A	N/A	7	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. BYSI, LTRN, EVAX, GNTA, and ENLV

How does Alzamend Neuro compare to BeyondSpring?

Summary

How does Alzamend Neuro compare to Lantern Pharma?

Summary

How does Alzamend Neuro compare to Evaxion A/S?

Summary

How does Alzamend Neuro compare to Genenta Science?

Summary

How does Alzamend Neuro compare to Enlivex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. BYSI, LTRN, EVAX, GNTA, and ENLV

How does Alzamend Neuro compare to BeyondSpring?

Which has more volatility & risk, ALZN or BYSI?

Does the media prefer ALZN or BYSI?

Which has stronger valuation & earnings, ALZN or BYSI?

Do analysts prefer ALZN or BYSI?

Do insiders & institutionals hold more shares of ALZN or BYSI?

Is ALZN or BYSI more profitable?

Summary

How does Alzamend Neuro compare to Lantern Pharma?

Which has more risk and volatility, ALZN or LTRN?

Which has better earnings and valuation, ALZN or LTRN?

Is ALZN or LTRN more profitable?

Do insiders and institutionals hold more shares of ALZN or LTRN?

Does the media prefer ALZN or LTRN?

Do analysts prefer ALZN or LTRN?

Summary

How does Alzamend Neuro compare to Evaxion A/S?

Is EVAX or ALZN more profitable?

Do analysts prefer EVAX or ALZN?

Do institutionals & insiders hold more shares of EVAX or ALZN?

Which has more volatility and risk, EVAX or ALZN?

Does the media favor EVAX or ALZN?

Which has higher earnings & valuation, EVAX or ALZN?

Summary

How does Alzamend Neuro compare to Genenta Science?

Do institutionals and insiders have more ownership in ALZN or GNTA?

Do analysts prefer ALZN or GNTA?

Is ALZN or GNTA more profitable?

Which has better earnings & valuation, ALZN or GNTA?

Does the media refer more to ALZN or GNTA?

Which has more volatility & risk, ALZN or GNTA?

Summary

How does Alzamend Neuro compare to Enlivex Therapeutics?

Do institutionals & insiders have more ownership in ENLV or ALZN?

Is ENLV or ALZN more profitable?

Which has higher valuation and earnings, ENLV or ALZN?

Does the media refer more to ENLV or ALZN?

Do analysts recommend ENLV or ALZN?

Which has more volatility & risk, ENLV or ALZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools